The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 25, 2006
Filed:
Aug. 04, 1999
David A. Sanders, West Lafayette, IN (US);
Richard J. Kuhn, West Lafayette, IN (US);
Scott A. Jeffers, West Lafayette, IN (US);
Curtis M. Sharkey, Lafayette, IN (US);
Cynthia L. North, Lafayette, IN (US);
Michael A. Fishbach, West Lafayette, IN (US);
David A. Sanders, West Lafayette, IN (US);
Richard J. Kuhn, West Lafayette, IN (US);
Scott A. Jeffers, West Lafayette, IN (US);
Curtis M. Sharkey, Lafayette, IN (US);
Cynthia L. North, Lafayette, IN (US);
Michael A. Fishbach, West Lafayette, IN (US);
Purdue Research Foundation, West Lafayette, IN (US);
Abstract
Cells that produce inventive pseudotyped retroviruses having a broad host range have been produced. In one aspect of the invention, the cells produce retroviruses pseudotyped with at least two different viral glycoproteins, such as togaviral glycoproteins. In alternative embodiments, the cells produce retroviruses pseudotyped with filoviral glycoproteins. Methods of producing the above-described cells, as well as the pseudotyped retroviruses thus produced, are also provided. In other embodiments, methods of screening agents effective in blocking viral entry into a cell, including filoviral entry or entry of viruses having at least two different viral glycoproteins disposed in their lipid bilayer, such as togaviruses, are provided. Moreover, methods of using the inventive pseudotyped retroviruses for introducing nucleotide sequences into target cells, and kits for forming the inventive pseudotyped retroviruses, are also provided.